Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Bank of America Securities Sticks to Their Hold Rating for Candel Therapeutics (CADL)

Tipranks - Tipranks - Sat Nov 15, 2025

In a report released today, Alec Stranahan from Bank of America Securities reiterated a Hold rating on Candel Therapeutics, with a price target of $7.00.

Meet Your ETF AI Analyst

Stranahan covers the Healthcare sector, focusing on stocks such as Revolution Medicines, Novavax, and Xencor. According to TipRanks, Stranahan has an average return of 4.2% and a 56.32% success rate on recommended stocks.

Candel Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $18.50.

See the top stocks recommended by analysts >>

Based on Candel Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $4.8 million. In comparison, last year the company had a GAAP net loss of $22.24 million

Read More on CADL:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).